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The hylEfm gene (encoding a putative hyaluronidase) has been found almost exclusively in Enterococcus
faecium clinical isolates, and recently, it was shown to be on a plasmid which increased the ability of E. faecium
strains to colonize the gastrointestinal tract. In this work, the results of mating experiments between hylEfm-
containing strains of E. faecium belonging to clonal cluster 17 and isolated in the United States and Colombia
indicated that the hylEfm gene of these strains is also carried on large plasmids (>145 kb) which we showed
transfer readily from clinical strains to E. faecium hosts. Cotransfer of resistance to vancomycin and high-level
resistance (HLR) to aminoglycosides (gentamicin and streptomycin) and erythromycin was also observed. The
vanA gene cluster and gentamicin resistance determinants were genetically linked to hylEfm, whereas erm(B)
and ant(6)-I, conferring macrolide-lincosamide-streptogramin B resistance and HLR to streptomycin, respec-
tively, were not. A hylEfm-positive transconjugant resulting from a mating between a well-characterized endocarditis
strain [TX0016 (DO)] and a derivative of a fecal strain of E. faecium from a healthy human volunteer (TX1330RF)
exhibited increased virulence in a mouse peritonitis model. These results indicate that E. faecium strains use a
strategy which involves the recruitment into the same genetic unit of antibiotic resistance genes and determinants
that increase the ability to produce disease. Our findings indicate that the acquisition of the hylEfm plasmids may
explain, at least in part, the recent successful emergence of some E. faecium strains as nosocomial pathogens.
Until the mid- to late 1980s, Enterococcus faecium was con-
sidered a “docile” organism; in fact, it was (and some strains
still are) used in the food industry as cheese or fermentation
starter cultures and as probiotics and was known to colonize
many animal species (26). The situation has changed substan-
tially in recent years, and isolates of E. faecium are now com-
monly recovered from infections seen in U.S. hospitals. In-
deed, in a recent report on health-care associated infections, E.
faecium accounted for 5.6% of isolates from health-care asso-
ciated infections; it was the third-most-common bacterial spe-
cies isolated after coagulase-negative staphylococci and Staph-
ylococcus aureus and was even more frequent than E. faecalis
(12). Moreover, 93% of vancomycin-resistant enterococcal iso-
lates from a recent survey of U.S. hospitals were E. faecium (9).
The ability of E. faecium to disseminate in the hospital envi-
ronment is thought to be due not only to the presence of
antibiotic resistance genes but also to the acquisition of deter-
minants which may increase the capacity of the organism to
survive in, colonize, and/or infect patients in the clinical set-
ting. However, in terms of virulence factors, E. faecium ap-
pears to lack certain important determinants, such as hemoly-
sin, gelatinase, and the fsr locus, previously shown to play a role
in Enterococcus faecalis infections (7). Aggregation substance,
encoded by pheromone-responsive E. faecalis plasmids, has
been found much less frequently in E. faecium (7). Previously,
a gene designated hylEfm, which encodes a protein with homol-
ogy to hyaluronidases, was postulated to be a potential viru-
lence factor of clinical isolates of E. faecium since this gene was
found to be more common in vancomycin-resistant E. faecium
isolates than in vancomycin-susceptible isolates of the same
species (21). Moreover, the hylEfm gene was not found in any of
186 fecal E. faecium isolates from community-based sources
(feces of healthy human volunteers, animals, probiotics, and
wastewater), whereas it was identified in 34% of 264 U.S. clinical
isolates ofE. faecium (21). The gene has also been associated with
isolates belonging to the genogroup referred to as clonal cluster
17 (CC17), a group of genetically related isolates that account for
the majority of E. faecium clinical isolates in hospitals worldwide
(26). Also, a plasmid carrying the hylEfm gene has been previously
shown to be an important factor for gastrointestinal colonization
in a mouse model (23). In this work, we studied the transferability
of the hylEfm gene along with antibiotic resistance genes from
clinical strains and characterized the role of the hylEfm-containing
plasmid in virulence in the mouse peritonitis model.
MATERIALS AND METHODS
Bacterial strains. The bacterial strains used in this work are shown in Table 1.
In order to simplify the strain nomenclature, we will refer to the names listed in
the second column of Table 1, which are different from the published strain
names (Table 1, first column). These bacteria include the hylEfm-positive (hylEfm)
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clinical isolates of E. faecium strain A [TX0016 (DO)] (http://www.hgsc.bcm.tmc
.edu) (19) and strain C (C-68) (4), both isolated in the United States, and strain
B (ERV-99), obtained in Colombia. The Colombian isolate B is a multidrug-
resistant E. faecium isolate recovered from the peritoneal fluid of a patient with
abdominal sepsis in February 2005. All clinical strains (A, B, and C, classified as
sequence type 16 [ST-16], ST-18, and ST-16, respectively) belong to CC17 by
multilocus sequence typing (MLST) (Table 1) (13). TX1330RF and D344SRF (a
pbp5-deficient E. faecium laboratory strain) (22) are rifampin (rifampicin)- and
fusidic acid-resistant derivatives generated from the parental strains by sequen-
tial selection on brain-heart infusion (BHI) agar containing inhibitory concen-
trations of each antibiotic. E. faecium TX1330RF-A1, TX1330RF-B1/-B2, and
D344SRF-C6 (23) are derivatives of TX1330RF and D344SRF to which hylEfm
from strains A, B, and C was transferred by mating (see below).
Filter matings, PFGE, and hybridizations. The hylEfm gene had been previ-
ously transferred by filter mating from the clinical isolate E. faecium C to
D344SRF (Table 1), resulting in the transconjugant D344SRF-C6, as described
previously (23). Similarly, hylEfm was transferred from clinical strains A and B to
TX1330RF by using the same mating approach (17), and transconjugants were
selected on medium supplemented with some antibiotics whose resistance de-
terminants are known to be transferable to determine if the resistance genes
cotransfer with hylEfm. Transconjugants from the strain A and TX1330RF mating
were selected on BHI agar supplemented with erythromycin (200 g/ml)-fusidic
acid (25 g/ml) and streptomycin (2,000 g/ml)-fusidic acid (25 g/ml). Single
colonies from each mating experiment were purified, grown on BHI agar (Difco
Laboratories, Detroit, MI) supplemented with rifampin (100 g/ml), and then
screened by PCR with primers 5-TTCTGAAACATGAACCATCA (forward)
and 5–TCAATATCATTTCCAGGACTAA (reverse) (nucleotides 398 to 674 of
the hylEfm gene). Ten hylEfm colonies from each experiment were further
characterized by pulsed-field gel electrophoresis (PFGE) (SmaI) and hybridiza
tions following a methodology described before (16) and using a probe generated
with the hylEfm primers. Transconjugants from the mating of strains B and
TX1330RF were selected on BHI agar supplemented with vancomycin (128 g/
ml)-fusidic acid (25 g/ml) and gentamicin (1,000 g/ml)-fusidic acid (25 g/ml).
Purified colonies from each mating were then grown on rifampin (100 g/ml).
Screening by PCR, PFGE (SmaI), and hylEfm hybridizations was then performed
as described above. SmaI digests of total DNA from the clinical strains A, B, and
C (donors) and corresponding selected transconjugant strains (TX1330RF-A1,
TX1330RF-B1 and TX1330RF-B2, and D344SRF-C6) were subsequently tra
nsferred to a nylon membrane and hybridizations performed with probes for
erm(B), aac(6)-aph(2) (25), ant(6)-I (25), and vanA (10), targeting genes
involved in resistance to macrolides and high-level resistance (HLR) to gentami
cin, streptomycin, and vancomycin, respectively. The erm(B) and ant(6)-I probes
were generated using DNA from strain A as template, whereas total DNA from
strain B was used to obtain the aac(6)-aph(2) and vanA probes.
Plasmid extractions, S1 nuclease/I-CeuI digestions, and hybridizations. In the
current work, plasmids from the D344SRF-C6 transconjugant (23) containing
the hylEfm gene were extracted by cesium chloride gradient centrifugation (8),
and the digested (EcoRI) fragments were transferred to a nylon membrane and
hybridized with the hylEfm probe. In order to confirm that hylEfm was present in
plasmids in the donor and transconjugant strains, an S1 nuclease assay was
performed by following the protocol of Barton et al. (3). This method allows the
detection and estimation of the size of large bacterial plasmids in the presence of
genomic DNA using PFGE and has been validated in gram-positive and gram-
negative organisms (3). Briefly, agarose gel plugs containing bacterial cells were
incubated for 45 min with 0.01 U of Aspergillus oryzae S1 nuclease (Sigma-
Aldrich, St. Louis, MO) in 200 l of 50 mM NaCl, 30 mM sodium acetate (pH
4.5), and 5 mM ZnSO4. Digested plugs were subjected to PFGE using the same
methodology described before (16). I-CeuI is an enzyme that recognizes specific
sequences found only in the 23S rRNA genes (14) and, thus, digests only bac-
terial chromosomes and can be used to differentiate the presence of extrachro-
mosomal elements (e.g., plasmids) using PFGE and hybridizations (6). I-CeuI
digests of bacterial strains were performed in agarose plugs, followed by sepa-
ration by PFGE as described previously (6). Subsequently, S1 and I-CeuI digests
were transferred to a nylon membrane and hybridized with a labeled hylEfm
probe (both S1 nuclease and I-CeuI digests) and with a probe targeting the 23S
rRNA genes obtained from the genome sequence of strain A (http://www.hgsc
.bcm.tmc.edu) (19) (I-CeuI digests only).
Antimicrobial susceptibility testing. The antimicrobial susceptibility profiles
of selected strains were determined by the agar dilution method for ampicillin,
vancomycin, and erythromycin; additionally, evaluation of the presence of HLR
to gentamicin and streptomycin was also performed. These susceptibility tests
were carried out following the Clinical and Laboratory Standards Institute
(CLSI) guidelines (5).
Mouse peritonitis model. Female (4- to 6-week-old), outbred ICR mice (Har-
lan Sprague Dawley, Houston) were used as previously described (24). Groups of
10 mice per inoculum (ranging from 1  108 to 4  109 CFU/ml) were included
in each experiment. Strains of E. faecium for inoculation were grown on BHI
agar (Difco Laboratories, Detroit, MI) and subsequently grown in BHI broth for
24 h at 37°C. Mice were injected intraperitoneally with 1 ml of a solution
containing one of the E. faecium strains in 50% suspended sterile rat fecal extract
(24) and monitored every 3 to 6 h for 120 h. Experiments were repeated at least
twice. Comparison of the survival curves at similar inocula was performed using
a log-rank test with Prism for Windows (GraphPad Software version 4.00); a
P value of 0.05 was considered significant.
RESULTS
Conjugative cotransfer of the hylEfm-containing plasmid and
antibiotic resistance genes. Since CC17 clinical strains A (ST-
16) and B (ST-18) harbor several antibiotic resistance genes
(15), we thought it possible that hylEfm and some of these genes
might be cotransferred by conjugation. Table 2 shows the
MICs of parent and transconjugant strains, which indicate that
resistance to erythromycin and vancomycin and HLR to strep-
tomycin and gentamicin were transferred to the recipient
TABLE 1. E. faecium strains used in this work
Published or
laboratory strain
nomenclature
Nomenclature used
for this work Relevant characteristics
a Presence of
hylEfm
Reference
TX0016 (DO) A Clinical isolate from the United States; Eryr Strr, ST-16 Yes 19
ERV-99 B Clinical isolate from Colombia; Vanr Genr, ST-18 Yes This study
C-68 C Clinical isolate from the United States; Vanr, ST-16 Yes 4
TX1330 TX1330 Susceptible fecal-colonizing strain from a healthy human volunteer No 19
TX1330RF TX1330RF Derivative of TX1330; Fusr Rifr No This study
TX2158 TX1330RF-A1 Derivative of TX1330RF to which the hylEfm-containing plasmid
was transferred by conjugation from strain A as donor; Eryr Strr
Yes This study
TX6068 TX1330RF-B1 Transconjugant resulting from a mating expt between strain B
(donor) and TX1330RF (recipient); Vanr Eryr Genr Strr
Yes This study
TX6069 TX1330RF-B2 Transconjugant resulting from a mating expt between strain B
(donor) and TX1330RF (recipient); Vanr Genr
Yes This study
D344SRF D344SRF Laboratory strain with spontaneous loss of pbp5; Fusr Rifr No 23
TC6 D344SRF-C6 Transconjugant resulting from a mating expt between strain C
(donor) and D344SRF (recipient)
Yes 24
a Eryr, erythromycin resistance; Fusr, fusidic acid resistance; Genr, HLR to gentamicin; Rifr, rifampin resistance; Strr, HLR to streptomycin; Vanr, vancomycin
resistance.
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strains. The conjugation efficiencies for resistance to erythro-
mycin and HLR to streptomycin in the TX1330RF mating with
strain A were 1.7  105 and 6.25  105 transconjugants per
donor, respectively, and 7 out of 10 colonies in each mating
experiment harbored hylEfm. On the other hand, among the
selected hylEfm
 transconjugants from the TX1330RF mating
with clinical strain B, the following two phenotypes were evi-
dent: (i) resistance to vancomycin and erythromycin and HLR
to both gentamicin and streptomycin represented by the
transconjugant strain TX1330RF-B1 and (ii) resistance only to
vancomycin and HLR to gentamicin (transconjugant
TX1330RF-B2) (Table 2). The conjugation efficiencies for van-
comycin resistance and HLR to gentamicin were 5.4  105
and 5.5  105 transconjugants per donor, respectively. All
selected vancomycin- and gentamicin-resistant transconjugants
from the strain B-TX1330RF mating carried the hylEfm gene
upon screening by PCR (10/10).
The hylEfm gene is carried on large transferable plasmids in
clinical strains of E. faecium. Previously, hylEfm was found to
be on a large transferable plasmid in strain C (23), a finding
that was confirmed here by cesium chloride plasmid extrac-
tions from strain D344SRF-C6 (a transconjugant resulting
from the mating of the clinical strain C and the laboratory
strain D344SRF) (23) and hybridization with a hylEfm probe
(data not shown). Therefore, we sought to investigate whether
hylEfm was carried similarly on plasmids in other clinical strains
of E. faecium belonging to CC17 and unrelated epidemiolog-
ically to the C strain. Thus, we performed S1 nuclease digests
with PFGE and hybridizations with a hylEfm probe using the
three E. faecium clinical strains and corresponding transcon-
jugants (Fig. 1). This method is very useful since large plasmids
appear as linearized bands in the presence of a faint genomic
DNA background, which allows the detection and estimation
of the size of large bacterial plasmids using PFGE (Fig. 1A).
The results showed that plasmid bands hybridizing with hylEfm
are present in all clinical strains and transconjugants but are
absent in the recipients (D344SRF and TX1330RF) (Fig. 1A),
confirming that hylEfm readily transfers as part of large plas-
mids from CC17 E. faecium strains. The plasmids appeared to
differ in size in the clinical strains, with the largest observed in
clinical strain A (running between 242.5 and 291 kb) and the
smallest in strain B (between 145 and 194 kb). Interestingly,
transfer of the hylEfm-containing plasmid from strains A and C
resulted in identical plasmid bands in the transconjugants;
however, conjugative plasmid transfer from clinical strain B
resulted in the following two events: (i) a transconjugant
(TX1330RF-B1) carrying a hylEfm-containing plasmid band
that was larger than that of the donor (Fig. 1A, lane 9) and (ii)
a second transconjugant (TX1330RF-B2) which appeared to
carry two hylEfm-containing plasmids, one similar in size to that
of the donor strain and an additional one of ca. 194 kb (Fig.
1A, lane 10). The extrachromosomal location of hylEfm was
confirmed by I-CeuI digestion, PFGE, and hybridization with a
hylEfm probe (Fig. 1B). I-CeuI recognizes a sequence in the
genes encoding the 23S rRNA, usually six copies for E. fae-
cium; thus, hybridization with a probe targeting the 23S rRNA
results in six chromosomal bands in each strain (Fig. 1B, center
panel). Conversely, hybridization with a hylEfm probe resulted
in bands that appeared as smears and did not correspond to
the chromosomal bands (Fig. 1B, left panel), suggesting the
presence of different forms of the plasmid.
Vancomycin resistance genes are physically linked to hylEfm
in the plasmids. The results for cotransfer of hylEfm and anti-
biotic resistance determinants led to the hypothesis that some
antibiotic resistance markers might be present on the same
mobilizable elements as the hylEfm gene. Thus, we generated
probes for genes commonly associated with resistance to van-
comycin (vanA) and erythromycin [erm(B)] and HLR to gen-
tamicin [aac(6)-aph(2)] and streptomycin [ant(6)-I] in E.
faecium and hybridized SmaI-digested total DNA of donor
strains and transconjugants after PFGE. In clinical strain A
and its transconjugant (TX1330RF-A1), hybridizations with
erm(B) and ant(6)-I yielded several bands of different molec-
ular weights that were clearly different from those hybridizing
with the hylEfm probe (Fig. 2A), suggesting that erm(B) and
ant(6)-I were likely to be on different genetic elements than
those carrying hylEfm. Conversely, the patterns of hybridization
of hylEfm were different in the two selected transconjugants
from the mating of clinical strain B (donor) and TX1330RF
(TX1330RF-B1 and TX1330RF-B2); the two transconjugants
also differed slightly in their SmaI PFGE pattern (Fig. 2B). In
TX1330RF-B2, two bands yielding a hylEfm signal were ob-
served (one of which was at the same level as the one hybrid-
izing with the hylEfm probe in the donor strain, B) (Fig. 2B, lane
4), whereas a single band of a higher molecular weight was
identified in the TX1330RF-B1 transconjugant (Fig. 2B, lane
3), confirming the results obtained with S1 nuclease digestion
(see above). Interestingly, hybridization patterns identical to
that of hylEfm were observed for the vanA gene in clinical strain
B and its transconjugants (Fig. 2B); the aac(6)-aph(2) probe
also hybridized to the same bands as hylEfm did, with the
exception of the transconjugant TX1330RF-B2, in which only
one band yielding a signal (instead of two) was detected (Fig.
2B). The results suggest that vancomycin resistance genes co-
transfer with the hylEfm-containing plasmid and that the gene
clusters are likely to be physically linked.
The hylEfm-containing plasmid increases virulence in exper-
imental peritonitis. The hylEfm
 TX1330RF transconjugant
(TX1330RF-A1) was compared to its parental strain (lacking
the hylEfm plasmid) in the mouse peritonitis model (24). Ac-
quisition of the hylEfm-containing plasmid by the transconju-
gant resulted in significantly decreased survival of mice in-
jected with different inocula and in experiments performed on
TABLE 2. MICs of E. faecium strains
Strain Presence ofhylEfm
MIC (g/ml)a HLRb
AMP VAN ERY GEN STR
A Yes 4 1 512  
TX1330RF No 1 0.5 0.5  
TX1330RF-A1 Yes 1 0.5 512  
B Yes 256 512 512  
TX1330RF-B1 Yes 1 128 512  
TX1330RF-B2 Yes 1 256 0.25  
C Yes 128 256 512  
D344SRF No 0.25 2 512  
D344SRF-C6 Yes 0.25 2 512  
a AMP, ampicillin; VAN, vancomycin; ERY, erythromycin.
b GEN, gentamicin; STR, streptomycin;  or , strain possesses or does not
possess HLR, respectively.
4242 ARIAS ET AL. ANTIMICROB. AGENTS CHEMOTHER.
different days (P 	 0.0006 and P 	 0.0133, respectively) (Fig.
3). The increased lethality was maintained even when a slightly
higher inoculum was used for the parental strain TX1330RF
(Fig. 3), indicating that acquisition of the hylEfm-containing
plasmid from E. faecium TX16 confers increased virulence in
vivo in the mouse peritonitis model.
DISCUSSION
To explain the changing trends in the epidemiology of E.
faecium, several studies have evaluated the possible association
of “epidemic” E. faecium isolates with putative virulence
genes. In Europe, the association of a gene called espfm (a
homolog of the E. faecalis esp gene) with isolates from CC17
has been reported (27); the espfm gene has been shown to be
transferable by conjugation (20), and it has also been noted to
be relevant for biofilm formation in vitro (11). Recently, an
intact acm gene, encoding a cell wall-anchored collagen adhe-
sin (the expression of which is enriched in CC17 isolates), was
shown in vivo to play an important role in E. faecium patho-
genesis in a rat model of endocarditis (18). However, the presence
of this gene did not increase virulence in the mouse model of
peritonitis (18), indicating that acm expression may not be as
important in other E. faecium infections. In the current study, we
present evidence for the first time that a plasmid plays a role in E.
faecium pathogenesis in the mouse peritonitis model and that this
plasmid contains the hylEfm gene and antibiotic resistance genes.
We also show that the hylEfm-containing plasmids from CC17
clinical strains isolated in different parts of the world were trans-
ferable by conjugation, confirming that the acquisition of the
hylEfm-containing plasmid may be a strategy to increase the in vivo
virulence or survival ability of nosocomial E. faecium strains. Us-
ing a combination of S1 nuclease and I-CeuI digestions and
PFGE (which have been shown to be accurate in the detection,
linearization, and size estimation of large plasmids) (3), we de-
termined that the hylEfm-containing plasmids are larger than 145
kb in all the clinical strains studied. The presence of such large
hylEfm-containing plasmids indicates that many potential genes
could participate and increase the pathogenic properties of E.
faecium carrying this plasmid. Although hylEfm has been the
focus of attention and has even been designated a “virulence
determinant” in several recent surveys worldwide (9, 28), the
FIG. 1. Results of S1 nuclease and I-CeuI digests, PFGE, and hybridizations. (A) S1 digestion of total DNA of E. faecium strains was followed
by PFGE (left panel) and hybridization with hylEfm (right panel). Lane 1, lambda ladder (molecular sizes in kilobases are shown to the left); lanes
2, strain C; lanes 3, transconjugant D344SRF-C6; lanes 4, D344SRF; lanes 5, clinical strain A; lanes 6, transconjugant TX1330RF-A1 (using strain
A as donor); lanes 7, TX1330RF (recipient); lanes 8, clinical strain B; lanes 9, transconjugant TX1330RF-B1 (using strain B as donor); lanes 10,
transconjugant TX1330RF-B2 (second transconjugant using clinical strain B as donor). Plasmid bands are shown as linearized fragments on the
gel; the white arrowheads indicate the plasmid bands hybridizing with hylEfm (right panel). (B) I-CeuI digestion of total DNA was followed by
PFGE (left panel) and hybridization with 23S rRNA (center panel) and hylEfm (right panel) probes. Lane 1, lambda ladder (molecular sizes in
kilobases are shown to the left); lanes 2, strain C; lanes 3, transconjugant D344SRF-C6; lanes 4, D344SRF; lanes 5, clinical strain A; lanes 6,
transconjugant TX1330RF-A1; lanes 7, TX1330RF; lanes 8, clinical strain B; lanes 9, transconjugant TX1330RF-B1; lanes 10, second transcon-
jugant, TX1330RF-B2. The figure is a composite of gels and hybridizations from different experiments.
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exact role of hylEfm in pathogenesis has not been elucidated
and our preliminary data indicate that this gene alone is not
sufficient to explain all the virulence properties of the plasmid
carrying it (not shown). In a previous study, the transfer of the
hylEfm-containing plasmid to E. faecium strains also conferred
an increased ability to colonize the gastrointestinal tract of
mice which was independent of the expression of antibiotic
resistance determinants (23). Therefore, it appears that E.
faecium isolates (mostly from the CC17 genotype) have re-
cruited important genes in a conjugative plasmid which appear
to play an important role in both virulence and colonization.
Similarly, the acquisition of antimicrobial resistance genes in
FIG. 2. Results of PFGE (SmaI digestion; leftmost panels) and hybridizations with hylEfm, erm(B), ant(6)-I, vanA, and aac(6)-aph(2) with E.
faecium strains. (A) Lane 1, lambda ladder; lanes 2, clinical strain A (TX16), lanes 3, transconjugant TX1330RF-A1 to which the hylEfm gene from
strain A was transferred; lanes 4, TX1330RF. (B) Lane 1, lambda ladder; lanes 2, clinical strain B; lanes 3, TX1330RF-B1 (transconjugant of
TX1330RF to which the hylEfm gene, resistance to vancomycin and erythromycin, and HLR to gentamicin and streptomycin from clinical strain B
were transferred); lanes 4, TX1330RF-B2 (second transconjugant of TX1330RF, to which the hylEfm gene, resistance to erythromycin, and HLR
to streptomycin from clinical strain B were transferred); lanes 5, TX1330RF. White arrowheads indicate the bands to which the hylEfm probe
hybridized. The figure was created using blots from different experiments.
FIG. 3. Survival of mice after intraperitoneal inoculation with E. faecium strains. Survival curves using strains TX1330RF and TX1330RF-A1
(TX1330RF transconjugant to which the hylEfm-containing plasmid was transferred) in the mouse peritonitis model (10 mice per group) at two
different inocula in independent experiments are shown.
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E. faecium poses immense therapeutic challenges for severe
infections caused by these organisms, with resistance emerging
to virtually all antibiotics used in clinical practice (1). In this work,
we also show that acquisition and cotransfer (with hylEfm) of
important antibiotic resistance determinants, such as those
conferring glycopeptide resistance, among others, readily oc-
cur, and we can draw the following conclusions from the results
of our mating experiments. (i) Antibiotic resistance genes also
cotransferred with the hylEfm-containing plasmid at relatively
high frequencies. (ii) Vancomycin resistance genes, as well as
aac(6)-aph(2) in transconjugant TX1330RF-B1, were physi-
cally linked to hylEfm and are likely to be in the same plasmid.
(iii) erm(B) and ant(6)-I appeared to be present in different
genetic elements (likely on a different plasmid which does not
have a SmaI restriction site) which, nonetheless, also cotrans-
fer with hylEfm, albeit at a lower rate of frequency. (iv) Gene
rearrangements of the hylEfm and vanA regions appeared to
occur during the conjugation process, leading to gene duplica-
tions and/or deletions; this may have resulted from the move-
ment of transposable elements with which hylEfm (21) and the
vanA gene cluster are known to be associated (2). The latter
point is illustrated by the results of the mating experiment
using the Colombian clinical strain B as donor. As opposed to
the mating experiments with clinical strains A and C which
resulted in transconjugants harboring hylEfm-containing plas-
mids of the same size (Fig. 1), conjugative transfer of the
hylEfm-containing plasmid from the B strain yielded plasmids
of different sizes. Furthermore, one of the recipients ended up
having two distinct hylEfm- and vanA-containing plasmids.
These findings support the hypothesis that movement and du-
plication of transposable elements containing hylEfm and van-
comycin-resistance genes to other plasmids can readily occur
during conjugative transfer in E. faecium clinical strains. Our
results illustrate the striking plasticity and adaptation of en-
terococci in the hospital environment to become a successful
pathogen; in a single genetic unit, these organisms are capable
of recruiting and transferring genes that could help with out-
competing other bacteria in the gut in the presence of antibi-
otics and at the same time increase their ability to produce
disease. The increasing prevalence of this multidrug-resistant
CC17 E. faecium containing a “virulence” plasmid in the
United States and Europe is a worrisome prospect.
In summary, our work indicates that large transferable plas-
mids containing the hylEfm gene cotransferred with antibiotic
resistance markers and that the acquisition of one of these
plasmids was associated with enhanced virulence of a commen-
sal strain of E. faecium. Thus, this single genetic unit appears
to enhance the colonizing, survival, and virulence properties of
members of the CC17 E. faecium genogroup.
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